Drug Profile


Alternative Names: BMS 626529 prodrug; BMS-663068; GSK 3684934; HIV attachment inhibitor - ViiV Healthcare; Temsavir prodrug

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; ViiV Healthcare
  • Class 2 ring heterocyclic compounds; Antiretrovirals; Phosphoric acid esters; Piperazines; Pyridines; Pyrroles; Small molecules; Triazoles
  • Mechanism of Action Virus attachment inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 12 May 2017 Bristol-Myers Squibb completes a phase IIb trial for HIV-1 infections (Combination therapy, Treatment-experienced) in USA, Argentina, Colombia, Mexico, Peru, South Africa, Germany, Romania, Spain and Russia (PO) (NCT01384734)
  • 15 Dec 2016 Biomarkers information updated
  • 08 Aug 2016 Bristol-Myers Squibb plans a phase I bioavailability trial in Healthy volunteers in USA (PO, Tablet) (NCT02859259)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top